The total number of records retrieved from this search are 5. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_4455	Virus nameHerpes simplex virus	Virus strainG47-delta-mCherry	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for Gamma 34.5, alpha47 and LacZ insertion inactivating ICP6	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineHuman patient	Origin of cell linemalignant leningioma	Cell lineMN298	Concentration of cell line4000 to 5000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.04 MOI	In-vitro result70% cell viablity after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26951380
IDOV_4459	Virus nameHerpes simplex virus	Virus strainG47-delta-mCherry	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for Gamma 34.5, alpha47 and LacZ insertion inactivating ICP6	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineHuman patient	Origin of cell linemalignant leningioma	Cell lineMN298	Concentration of cell line4000 to 5000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.11 MOI	In-vitro result55% cell viablity after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26951380
IDOV_4463	Virus nameHerpes simplex virus	Virus strainG47-delta-mCherry	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for Gamma 34.5, alpha47 and LacZ insertion inactivating ICP6	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineHuman patient	Origin of cell linemalignant leningioma	Cell lineMN298	Concentration of cell line4000 to 5000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.33 MOI	In-vitro result50% cell viablity after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26951380
IDOV_4467	Virus nameHerpes simplex virus	Virus strainG47-delta-mCherry	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for Gamma 34.5, alpha47 and LacZ insertion inactivating ICP6	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineHuman patient	Origin of cell linemalignant leningioma	Cell lineMN298	Concentration of cell line4000 to 5000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration1 MOI	In-vitro result30% cell viablity after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26951380
IDOV_4471	Virus nameHerpes simplex virus	Virus strainG47-delta-mCherry	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for Gamma 34.5, alpha47 and LacZ insertion inactivating ICP6	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineHuman patient	Origin of cell linemalignant leningioma	Cell lineMN298	Concentration of cell line4000 to 5000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration3 MOI	In-vitro result25% cell viablity after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26951380